Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study-Reference-Cited by-同舟云学术

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

Published:2001-04 Issue:4 Volume:29 Page:765-769
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:Critical Care Medicine

Author:

Reinhart Konrad,Menges Thilo,Gardlund Bengt,Harm Zwaveling Jan,Smithes Mark,Vincent Jean-Louis,Maria Tellado Jose,Salgado-Remigio Antonio,Zimlichman Reuven,Withington Stuart,Tschaikowsky Klaus,Brase Rainer,Damas Pierre,Kupper Hartmut,Kempeni Joachim,Eiselstein Juergen,Kaul Martin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference22 articles.

1. Anti-Endotoxin Monoclonal Antibodies — A Second Look

2. Management of Septic Shock: Present and Future

3. Has the mortality of septic shock changed with time?

4. Shock and Tissue Injury Induced by Recombinant Human Cachectin

5. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Divergent effects of tumor necrosis factor (TNF) in sepsis: a meta-analysis of experimental studies;Critical Care;2024-09-04

2. The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review;New Microbes and New Infections;2024-08

3. Evolving Paradigms in Sepsis Management: A Narrative Review;Cells;2024-07-09

4. GENETIC ABLATION OF THE C-TYPE LECTIN RECEPTOR CLEC2D INCREASES PERITONITIS MORTALITY, INFLAMMATION, AND PHYSIOLOGY WITHOUT DIMINISHING ORGAN INJURY;Shock;2024-06-11

5. Towards personalized medicine: a scoping review of immunotherapy in sepsis;Critical Care;2024-05-28